drug

Delta-9-THC

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Yale University
4 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

4
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
NCT04605393—Completed
The Effects of Cannabidiol and ∆-9-THC in Humans
NCT01180374Early Phase 1Completed
N-acetylcysteine Effects on Tetrahydrocannabinol
NCT02335060Early Phase 1Terminated
The Effects of ∆-9-THC and Naloxone in Humans
NCT01591629Early Phase 1Completed

KOLs & investigators

3
Mohini Ranganathan, M.D.KOL score 5
Mohini Ranganathan, MBBSKOL score 5
Gill Dale

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Yale University
company
trial
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
NA
trial
The Effects of Cannabidiol and ∆-9-THC in Humans
EARLY_PHASE1
trial
N-acetylcysteine Effects on Tetrahydrocannabinol
EARLY_PHASE1
trial
The Effects of ∆-9-THC and Naloxone in Humans
EARLY_PHASE1
trial
indication
Schizophrenia
indication
Healthy
indication
Marijuana Abuse
indication
Schizophrenia
indication
KOL
Mohini Ranganathan, M.D.
KOL score 5
person
Mohini Ranganathan, MBBS
KOL score 5
person
Gill Dale
KOL score —
person